| All Releases |
|---|
 |
EpiCept Corporation Reports Third Quarter Results, Provides Business Update
Nov 10, 2009
|
29.2 KB
|
| |
TARRYTOWN, N.Y., Nov 10, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced operating and financial results for the three and nine months
ended September 30, 2009, and provided an update on Ceplene(R) and several
of the Company's key product candidates. Ceplen...
|
|
|
EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application for Review
Nov 9, 2009
|
12.0 KB
|
| |
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Health Canada has accepted for review the Company's New
Drug Submission (NDS) for Ceplene(R) (histamine
dihydrochloride) for the remission maintenance of acute myeloid leukemia
...
|
|
|
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing
Nov 6, 2009
|
11.7 KB
|
| |
TARRYTOWN, N.Y., Nov 06, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it has appointed Bernard R. Tyrrell as the Company's
Senior Vice President, Sales and Marketing, a newly created position.
Mr. Tyrrell joins EpiCept with a wealth of experience in...
|
|
|
EpiCept to Report Third Quarter 2009 Operating and Financial Results on November 10, 2009
Nov 5, 2009
|
11.6 KB
|
| |
TARRYTOWN, N.Y., Nov 05, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will host a conference call to discuss third quarter
2009 operating and financial results on Tuesday, November 10, 2009 at
9:00 a.m. EST. The call will follow the release of th...
|
|
|
Nasdaq Panel Grants EpiCept's Request for Continued Listing
Nov 3, 2009
|
11.1 KB
|
| |
TARRYTOWN, N.Y., Nov 03, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that a Nasdaq Hearings Panel has granted the Company's request
for continued listing on The Nasdaq Stock Market. The Company's
continued listing is subject to the Company's satisfactio...
|
|
|
EpiCept to Present at BIO-Europe 2009
Nov 2, 2009
|
11.1 KB
|
| |
TARRYTOWN, N.Y., Nov 02, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Jack Talley, President and CEO, will be presenting at the
BIO-Europe 2009 Conference on November 3, 2009 at 2:15 p.m. local time
at the Hilton Vienna Danube Hotel in Vienna, Austr...
|
|
|
New Data Supports Pharmacoeconomic Benefits of Ceplene(R)
Oct 26, 2009
|
12.5 KB
|
| |
TARRYTOWN, N.Y., Oct 26, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announces the
release of new findings demonstrating the pharmacoeconomic benefits of
Ceplene(R) (histamine dihydrochloride) for the remission
maintenance of Acute Myeloid Leukemia (AML) patients in fi...
|
|
|
EpiCept's Ceplene(R) Highlighted in Two 2008 European Union Drug Approval Reports
Sep 3, 2009
|
11.7 KB
|
| |
TARRYTOWN, N.Y., Sep 03, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Ceplene(R) (histamine dihydrochloride) has been
highlighted in two separate reports issued recently reviewing 2008 drug
approvals in the European Union. One report, issued by the ...
|
|
|
EpiCept Corporation to Present at the Rodman & Renshaw Healthcare Conference
Sep 2, 2009
|
11.2 KB
|
| |
TARRYTOWN, N.Y., Sep 02, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Jack Talley, President and CEO, will be presenting at the
Rodman & Renshaw 11th Annual Healthcare Conference. The
presentation is scheduled for September 9, 2009 at 3:15 pm Easter...
|
|
|
EpiCept Corporation Reports Second Quarter 2009 Operating and Financial Results, Provides Business Update
Aug 6, 2009
|
28.5 KB
|
| |
TARRYTOWN, N.Y., Aug 06, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced operating and financial results for the three and six months
ended June 30, 2009. For the second quarter of 2009, the net loss
attributable to common stockholders declined 9% to $7.1 m...
|
|
|
EpiCept Announces Filing of New Drug Submission for Approval of Ceplene in Canada
Aug 5, 2009
|
11.6 KB
|
| |
TARRYTOWN, N.Y., Aug 05, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it has filed a New Drug Submission (NDS) with Health
Canada for Ceplene(R) (histamine dihydrochloride) for the
treatment of acute myeloid leukemia (AML) patients in first complete...
|
|
|
EpiCept to Report Second Quarter 2009 Operating and Financial Results on August 6, 2009
Aug 3, 2009
|
11.7 KB
|
| |
TARRYTOWN, N.Y., Aug 03, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will host a conference call to discuss second quarter
2009 operating and financial results on Thursday, August 6, 2009 at 9:00
a.m. Eastern time. The call will follow the relea...
|
|
|
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Jul 10, 2009
|
12.8 KB
|
| |
TARRYTOWN, N.Y., Jul 10, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced the start of a post-approval clinical study with Ceplene(R) (histamine
dihydrochloride) following Ethics Committee and Competent Authority
approvals in Sweden, Belgium, and France. Thi...
|
|
|
EpiCept Announces Results of Annual Meeting of Stockholders
Jul 3, 2009
|
13.0 KB
|
| |
TARRYTOWN, N.Y., Jul 03, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today the results of its 2009 Annual Meeting of Stockholders held on
June 2, 2009 in Stockholm, Sweden. The meeting was adjourned in order to
provide the company time to secure additional pr...
|
|
|
EpiCept Shares on the OMX Nordic Exchange Transferred Back to Ordinary Position from Observation Segment
Jun 29, 2009
|
11.2 KB
|
| |
TARRYTOWN, N.Y., Jun 29, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that its common stock traded on the OMX Nordic Exchange in
Stockholm has been removed from the observation segment and transferred
back to its ordinary position on the Exchange as of t...
|
|
|
EpiCept Announces Pricing of Public Offering
Jun 19, 2009
|
12.4 KB
|
| |
TARRYTOWN, N.Y., Jun 19, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today that it entered into definitive agreements for the purchase of
approximately 12.0 million shares of its common stock at $.80 per share
and two-and-one-half-year warrants to purchase up...
|
|
|
EpiCept Corporation to Present at the 5th Annual Noble Financial Equity Conference
Jun 5, 2009
|
11.4 KB
|
| |
TARRYTOWN, N.Y., Jun 05, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Jack Talley, President and CEO, will be presenting at the
5th Annual Noble Financial Equity Conference on Tuesday, June
9, 2009 at 8:40 a.m. Eastern Time. The conference will be h...
|
|
|
EpiCept Releases New Data Demonstrating Long-Term Durability of Ceplene in Sustaining Leukemia-Free Survival
Jun 4, 2009
|
12.3 KB
|
| |
TARRYTOWN, N.Y., Jun 04, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has released
new long-term data showing that the use of Ceplene(R)
when administered in conjunction with low-dose interleukin-2 (IL-2)
provides durable protection from leukemia relapse in patients wit...
|
|
|
EpiCept Partners With IDIS For Ceplene(R) Named Patient/Compassionate Use Program
Jun 2, 2009
|
14.2 KB
|
| |
TARRYTOWN, N.Y., Jun 02, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it has signed an agreement with IDIS, a private,
U.K.-based company, to administer a Named Patient Program for Ceplene(R),
EpiCept's proprietary therapy approved in the European U...
|
|
|
EpiCept Announces Webcast of Annual Meeting of Stockholders
May 29, 2009
|
11.5 KB
|
| |
TARRYTOWN,N.Y., May 29, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that its annual meeting of stockholders will be accessible to
investors via webcast. The annual meeting will be held on June 2, 2009
at 4:00pm Stockholm time (10:00 am Eastern time) at ...
|
|
|
